Stock AnalizAbivax S.A. ABVX
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
Abivax S.A. (ABVX) is a healthcare company listed in the US with a market value of about $7.6B. In fiscal year 2025 it had revenue of $5M and net income of -$395M, a net margin of -7354.5%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -319%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $5M | $13M | $5M | $5M | $14M |
| Net income | -$395M | -$183M | -$163M | -$65M | -$48M |
| Free cash flow | -$189M | -$161M | -$108M | -$58M | -$51M |
| EPS (diluted) | $-4.53 | $-2.10 | $-1.87 | $-0.74 | $-0.55 |
| Net margin | -7354.5% | -1415.7% | -3197.1% | -1325.3% | -354.9% |
| ROIC | -42.7% | -426.2% | -65.0% | -901.9% | -159.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Abivax pay a dividend?
Not currently.
Is Abivax a good stock to buy?
We do not give buy or sell advice. Abivax scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.